Back to Search
Start Over
Technology evaluation: CpG-7909, Coley.
- Source :
-
Current opinion in molecular therapeutics [Curr Opin Mol Ther] 2003 Oct; Vol. 5 (5), pp. 553-9. - Publication Year :
- 2003
-
Abstract
- Coley Pharmaceutical (formerly CpG ImmunoPharmaceuticals) is developing CpG-7909 (ProMune) for use in the potential treatment of cancer and as a vaccine adjuvant. By April 2000, CpG-7909 had entered phase I/II trials for cancer and in March 2002, Coley initiated a phase I trial in non-Hodgkin's lymphoma in combination with rituximab (Rituxan). By October 2002, CpG-7909 was in phase II trials as a vaccine adjuvant. Cpg-7909 is currently also undergoing phase II trials for melanoma.
- Subjects :
- Adjuvants, Immunologic pharmacokinetics
Animals
Antineoplastic Agents pharmacokinetics
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
CpG Islands
DNA-Binding Proteins immunology
DNA-Binding Proteins metabolism
Hepatitis B drug therapy
Humans
Oligodeoxyribonucleotides pharmacokinetics
Oligodeoxyribonucleotides, Antisense metabolism
Receptors, Cell Surface immunology
Receptors, Cell Surface metabolism
Toll-Like Receptor 9
Adjuvants, Immunologic therapeutic use
Antineoplastic Agents therapeutic use
Neoplasms drug therapy
Oligodeoxyribonucleotides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1464-8431
- Volume :
- 5
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Current opinion in molecular therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 14601526